"Insurmountable lead"...

...was the description of Genta's headstart on all other antisense development.

WOW

YUP! Great stuff!! LOL!

Shorts have met their end!

Webcast presentation in 24 minutes!

http://webcastingplayer.corporate-ir.net/player/LrgPlayer.aspx?EventId=2079510&StreamId=1260249&TIK={8CEC9688-9089-484E-ABC1-DBB417AFD647}&RGS=1&override=lrg

Yep, I would like to hear it...

...as an investor, but I'm not overly concerned about it. With approval of Genasense or Tesetaxel for any application, it really won't matter with where I'm trying to go.

Should be a great overview for Genta today...

...I'm looking forward to hearing the latest on what this company is doing for the community and its shareholders.

Here's the LINK!

Get your coffee and let's get the show on the road.

http://webcastingplayer.corporate-ir.net/player/LrgPlayer.aspx?EventId=2079510&StreamId=1260249&TIK=%7B8CEC9688-9089-484E-ABC1-DBB417AFD647%7D&RGS=1&override=lrg

Healthcare and Biotech - Big Week at the Waldorf Astoria
Posted by Barbara Lavery on February 2, 2009 at 1:07 pm

Don't plan a trip to the Waldorf Astoria next week unless you are into healthcare and biotech or have a penchant for fighting your way through a sea of bankers and anxious CEOs.

Both the UBS Healthcare Services conference and the annual BIO CEO meeting will descend on New York on Sunday 8th through mid-week.

Under one roof will be the more than 1,500 portfolio managers, analysts, and investors at UBS and over 800 investors and close to 200 companies at BIO CEO.

UBS features presentations by senior executives from firms representing acute care, alternate site, distribution, healthcare REITs, information technology, laboratory services, long-term care, managed care, pharmaceutical services, staffing, and other sub-sectors. I could not find a list of presenters for this year but individual companies are issuing press releases so you can track attendees using a Google news search

BIO CEO features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities. Presenting companies are listed on the BIO CEO website.

Importantly this year, the BIO folks have also invited 12 patient advocacy and disease research groups to present.

That's a lot of movers and shakers in one place at one time - the money, the patients, the delivery technologies, and the medicines of the future!

Now if only we could get Obama's healthcare team and new FDA commissioner to work the lobby we could get a lot done in short order!

See you in New York!

http://www.zoomedia.com/zoomedia_blog/item/it_1233610134

What are you talking about?

Genta has a drug on the market and another that is given on a named patient basis. The shit ain't free.

Do some research before you make yourself sound even more like an idiot with your all caps.

Conclusion:

From the FDA website...

http://www.fda.gov/Fdac/features/2002/402_drug.html

Manufacturing issues are also among the reasons that approval may be delayed or denied. Drugs must be manufactured in accordance with standards called good manufacturing practices, and the FDA inspects manufacturing facilities before a drug can be approved. If a facility isn't ready for inspection, approval can be delayed. Any manufacturing deficiencies found would need to be corrected before approval.

"Sometimes a company may make a certain amount of a drug for clinical trials. Then when they go to scale up, they may lose a supplier or end up with quality control issues that result in a product of different chemistry," says the FDA's Kweder. "Sponsors have to show us that the product that's going to be marketed is the same product that they tested."
____________________________________________________________

Now, from the Genta website on their open job requisition...connect the dots, people.

****Sr. Director, Manufacturing Operations****

This position reports to the COO and will be responsible for the production of API and drug product at third parties under strict cGMP conditions while maintaining safety and quality , and assuring COG margins are met through optimization programs.

Responsibilities:

* Direct the development, planning, implementation and maintenance of manufacturing methods and operations for all products and technologies at third parties.
*Assure effective relationships with third parties (vendors and partners) who provide API.
* Provide technical support to the sites and manufacturing engineering as new facilities, products, and processes are introduced.
* Lead productivity team to drive down cost while maintaining quality and safety.
* Lead scale-up and validation of drug substances, drug product and analytical methods.
* Negotiate with contract manufacturers who supply clinical and commercial material.
* Represent manufacturing at internal and external meetings.
* Plan production and distribution of API.
* Manage production forecasts through careful planning and interaction with internal colleagues and third parties.
______________________________________________________________

I'll laugh my ass off if people miss out on this opportunity due to CURRENT manufacturing capability reasons that can be EASILY mitigated.

Message 2 of 2:

A common non-approval response from the FDA can be given due to the current inability to mass produce a drug submitted in an NDA (see post 1 of 2 just before this one). Words are important. The FDA said that it couldn't approve Genasense in CLL "in its current form." Could be coincidence, but Genta is looking to hire a new position to their team.

Sr. Director, Manufacturing Operations

This position reports to the COO and will be responsible for the production of API and drug product at third parties under strict cGMP conditions while maintaining safety and quality , and assuring COG margins are met through optimization programs.

Responsibilities:

* Direct the development, planning, implementation and maintenance of manufacturing methods and operations for all products and technologies at third parties.
* Assure effective relationships with third parties (vendors and partners) who provide API.
* Provide technical support to the sites and manufacturing engineering as new facilities, products, and processes are introduced.
* Lead productivity team to drive down cost while maintaining quality and safety.
* Lead scale-up and validation of drug substances, drug product and analytical methods.
* Negotiate with contract manufacturers who supply clinical and commercial material.
* Represent manufacturing at internal and external meetings.
* Plan production and distribution of API.
* Manage production forecasts through careful planning and interaction with internal colleagues and third parties.

Qualifications:

* Advanced Degree in Biology, Chemistry, Chemical Engineering or Pharmacy (PhD preferred)
* 15+ year's industry experience in a pharmaceutical or biotechnology environment including knowledge of all aspects of the manufacturing process, technology, product development and commercialization.
* Experience in transferring processes for bulk API's and intermediates, knowledge of regulatory requirements for bulk API's, and a strong background in analytical methodology as related to release of bulk API's, intermediates, and starting materials.
* At least 3 - 5 years experience directly supervising professionals and demonstrated ability to effectively lead a team.
* Strong knowledge of governmental regulations regarding manufacture and distribution of pharmaceutical entities.
* Demonstrated success negotiating with vendors and managing third party alliances in a dynamic environment.
* Proven ability to work effectively with internal colleagues by leveraging strong communication and interpersonal skills.
* High degree of comfort managing and leading in a dynamic environment.

Travel Requirements: Approximately 25% travel.

Message 1 of 2:

Understanding "Bumps in the Road"

Bumps in the Road

If the FDA decides that the benefits of a drug outweigh the risks, the drug will receive approval and can be marketed in the United States. But if there are problems with an NDA or if more information is necessary to make that determination, the FDA may decide that a drug is "approvable" or "not approvable."

A designation of approvable means that the drug can probably be approved, provided that some issues are resolved first. This might involve the sponsor and the FDA coming to a final agreement on what should go on the drug's labeling, for example. It could also involve more difficult issues, such as the adequacy of information on how people respond to various dosages of the drug.

A designation of "not approvable" describes deficiencies significant enough that it is not clear that approval can be obtained in the future, at least not without substantial additional data.

Common problems include unexpected safety issues that crop up or failure to demonstrate a drug's effectiveness. A sponsor may need to conduct additional studies--perhaps studies of more people, different types of people, or for a longer period of time.

Manufacturing issues are also among the reasons that approval may be delayed or denied. Drugs must be manufactured in accordance with standards called good manufacturing practices, and the FDA inspects manufacturing facilities before a drug can be approved. If a facility isn't ready for inspection, approval can be delayed. Any manufacturing deficiencies found would need to be corrected before approval.

"Sometimes a company may make a certain amount of a drug for clinical trials. Then when they go to scale up, they may lose a supplier or end up with quality control issues that result in a product of different chemistry," says the FDA's Kweder. "Sponsors have to show us that the product that's going to be marketed is the same product that they tested."

John Jenkins, M.D., director of CDER's Office of New Drugs, says, "It's often a combination of problems that prevent approval." Close communication with the FDA early on in a drug's development reduces the chance that an application will have to go through more than one cycle of review, he says. "But it's no guarantee."

The FDA outlines the justification for its decision in an action letter to the drug sponsor. When the action is either approvable or not approvable, CDER gives the sponsor a chance to meet with agency officials to discuss the deficiencies. At that point, the sponsor can choose to ask for a hearing, or correct any deficiencies and submit new information, or they can withdraw the application.

http://www.fda.gov/Fdac/features/2002/402_drug.html

CONTINUED ON NEXT POST

Thinking about joining the party, guys.

Please...

...stop spamming this board with other companies BS.

Speak GNTA or get lost.

There has been tremendous...

...DD done here over the weekend, and posts like yours referencing other companies is very counterproductive to what we're trying to do here on the GNTA board.

People come here to learn about what's going on with Genta, not some other company. So, please, PLEASE take your spamming somewhere else and quit knocking the great work GNTA supporters have contributed off the front page. It's highly disrespectful and boarderline malicious.

After hearing yet another compelling presentation from Genta on Monday, with additional confirmatory trial results, I am going to find it very surprising if one of these participating investors doesn't see this as a great opportunity.

Participating Investors


1798 Global Partners
A.M. Pappas & Associates, LLC
Aberdeen Asset Management
Aceras BioMedical, LLC
Accipiter Capital Management
Actin Biomed
Aduro Capital LLC
Advent Capital Management
AgeChem Financial
AIG Global Investment Group
Aisling Capital
AllianceBernstein
AM Investment Partners
Amphion Innovations
Arcoda Capital
Arcus Ventures
Ardana Capital Management
Ares Life Sciences
Arnhold and S Bleichroeder Advisers
Array Capital Management, LLC
Ascent Biomedical Holdings (ABH)
Atypical BioCapital Management LLC
Axiom Venture Partners
Bailard, Inc.
Baker Brothers Investments
Banc of America Securities/Merrill Lynch
Barclays Capital
BBL Biomedical
BDR Research Group
BioRevolution Capital, LLC
Biotechnology Value Fund
Black Diamond Advisers
BladeRock Capital
Bloom Burton & Co.
Blumberg Capital Management
BMS Strategic Venture
Boenning & Scattergood
Brean Murray
Bridger Capital
Broadfin Capital
BSI Healthcapital SA
Caledonian Private Equity
Camber Capital Management
Canaccord Adams
Capital Midwest Fund
Capstone Investments
Care Capital LLC
Carlyle Blue Wave
Catapult Capital
Cato BioVentures
Caxton Advantage Venture Partners
CCI Healthcare Partners
Celtic Therapeutics LP
Charlestown Capital Advisors, LLC
Chilton Investment Company
CHL Medical Partners
Citi
CLC
Collins Stewart
Columbia Management Advisors
Cowen Healthcare Royalty Partners
CR Intrinsic
Cummings Bay Capital
Dabar Investment Associates
DD Venture Fund
Deerfield Management
Delaware Investments
Delwar Capital
Diker Management
DRI Capital
DSM Capital
Eagle Asset Management
East Hill Management Company
Easton Capital
EGB Ventures
EGS Healthcare Capital Partners
Emerald Asset Management Inc.
Emergent Medical Partners
Eminent Venture Capital Corporation
EuclidSR Partners, LP
Fidelity - Pyramis Global Advisors
Fidelity Investments
First Island Capital, Inc
FMB Research
FMG
Forest Investment Management
ForeThought
Fortis Investments
Fortress Investment Group
Fountain Healthcare Partners
Fred Alger
Fremont Ventures
Furgueson Capital Management
Fusion Capital Partners
The Galleon Group
Garrison, Bradford & Associates
Geneva Investment Management
George Weiss Associates
GGS Capital
GMA Capital LLC
Goldman, Sachs & Co
Great Point Partners
Griffin Securities, Inc.
Hambrecht & Quist Capital
Hapoalim Securities USA
Harbor Watch Capital Management
HCI Advisors
Healthcare Value Capital
Healthcor Management, LP
Helix Management
H.I.G. Ventures
Highside Capital Management
HK & Associates
Horizon Technology Ventures
Icahn Capital LP
Investor Growth Capital
The Invus Group
Issaquena Trust
J&J Development Corporation
J Goldman & Co
JAFCO Life Science Investment
Jefferies and Co
Jina Ventures
JMP Securities
JP Morgan
Johnston Associates Inc.
JW Asset Management
Katz Associates
Kingdon Capital Management
Kingsbridge Capital
KMD Ventures
Knoll Capital Management, LP
Knott Partners, LP
L Capital Partners
Ladenburg Thalmann & Co
Lazard Asset Management
Lazard Capital Markets
Ledgemont Capital
Leerink Swan, LLC
Legg Mason
Life Science Partners
LifeScience EquityPartners, LLC
Liss Investments
Little Gem Life Sciences
Loeb Partners
Logical Ventures
Lord Abbett & Co.
Mackay Shields
Maple Leaf Partners
Maven Biocapital LLC
Maxim Group
Mayfair Capital Partners, Inc
Mazama Capital Management
MC Life Science Ventures (Mitsubishi)
MD Becker Parners LLC
MedImmune Ventures
Mentor Capital Partners Ltd
Merriman Curhan Ford
Miller Tabak
Montaur Capital
Morgan Stanley
MP Asset Managers
MP Healthcare Venture
MPM Capital
Mymensingh Partners
Natixis Bleichroeder, Inc.
NDI Capital Inc.
Needham & Co
NeoMed Management
NeuroVentures Capital
New Enterprise Associates
New Leaf Venture Partners
Nextech Manager LLC
NextStep Capital
NGN Capital LLC
NJTC Venture Fund
Nobel Financial
Novartis Option Fund
Novo A/S
Number One Corporation
Nutmeg Securities Ltd
Olayan Group
Omega Funds
OneLife Advisors SA
OppenheimerFund
Oracle Investment Management
OrbiMed Advisors
OrbiMed Advisors India Private Limited
OSS Capital
Outer Islands Capital
Pacific Rim Ventures
Paisley and Habermas, Inc.
Paperboy Ventures LLC
Pappas Ventures
Passport Capital
Paul Capital Healthcare
Paulson Capital
Paw Partners
Perceptive Advisors
Perseus, LLC
Pioneer Investments
Piper Jaffray
POSCO BioVentures
PricewaterhouseCoopers
Princeton Capital Management Inc.
Principled Capital Management
QuestRion
QVT Financial LP
Radius Ventures
Ram Partners, LP
RBC Capital Markets
Red Abbey Venture Partners
Redmile Group
ReqMed Company, Ltd
Revach Fund LP
Ridgeback Capital Management
Ridgemark Capital
Roche
Rodman & Renshaw
Royal Investments LLC
Royalty Pharma
RRC
SCM
S Squared Technology Corp.
SAC Capital
Sagamore Capital
Scimitar Equity, LLC
SCO Capital Partners
Sectoral Asset Management
Sems Capital LLC
Sherbrook Capital Management, LLC
Sichel Medical Ventures
Sio Capital Management
Sit Investment Associates
Skyline Ventures
Special Situation Funds
Spiro Capital Management, Inc.
SPRI Clinical Trials
SR One
Standard Life Investments
Stanford Group Company
Strauss Asset Management
Stuyvesant Capital Partners
Suffolk Capital Management
Summer Street Research Partners
Sunrise Equity Partners
Susquehanna
SV Life Sciences
Symbios Partners LLC
Symmetry Capital
Symphony Capital LLC
T.Rowe Price
Tanaka Capital Management
Tang Capital Management, LLC
The Channel Group, LLC
ThinkEquity
Thomas, McNerney & Partners
Thomas Weisel Partners
Thomson Reuters
Titan Capital Management
Tocqueville Asset Management
Tokum Capital Management
Triple Peak Capital
Turner Investment Partners
TVM Capital
Two River Group Holdings, LLC
UBS Global Asset Management
Vanadium Capital Management
Venrock
Ventures West Capital
Vision Capital Advisors
Visium Asset Management
Wachovia Capital Markets, LLC
Wafra Investment Advisory Group
WBB Securities, LLC
Wedbush Pacific Growth Life Sciences
Weiss Multi-Strategy Advisors
Westfield Capital Management Co.
Wexford Capital LLC
Winslow Management Company
World Technology Ventures, LLC
Yasuda Enterprise Development America Inc
Yorkville Advisors
Young Capital Partners
Xmark Opportunity Partners

And that my friend....

...is why I'm letting my money ride on Genta.

Outstanding overview.

Extremely Bullish Trend: Lopsided Breast Breakout

Courtesy of DayTrader



Either you're buying or you're holding. But you're definitely not letting go.

I bet Merel is...

...pretty tired of hearing from you everyday.

That's not accurate...

...Warrell and Itri are married. As a couple, they purchased 637,634 shares in December when the stock price was beaten down to its lowest.

http://pinksheets.com/pink/quote/quote.jsp?symbol=gnta#getInsiderTrans

They bought at lower levels....

...keep in mind that the insider buys you see in December were right after the stock plummeted. They knew they were undervalued.

Yup...

...what a beast.

Hey griff!

Glad to see you're back again to eat some crow. I told you way back at .0022 that we were undervalued. You and your buddy Durango liked to get on here and run your trap, didn't ya?

Haha, GNTA would be the best performing stock in your portfolio if you weren't such a know it all back then.

Way to go buddy!

LOL

No, Nate...

...you're here for self-validation hoping you made a good trade. You'll soon see it was a bad idea to get out with so much on the line for the company.

Best of luck in future efforts.

Look at the progression on the charts...

...since December, then make an educated guess on what this stock will continue to do.

Don't let some random poster come on board and shake you out of your position here. There's too much on the line and posters like THAT guy will be the ones who never, ever make any real money in this game.

Don't take your chips off the table.

I looked into what you posted...

...and found that volume and share price only spiked the day before the trade show in 2008. It's not as if there was a continued interest in buying over weeks and weeks like there has been with GNTA in 2009. It was a one day spike. This year is completely different, momentum and buying interest has been increasing for over a month with textbook bullish patterns. Add to the mix that Ganite is now on the market, Tesetaxel has been granted orphan drug status, and Genasense is producing incredible results in melanoma with the Agenda Phase III trial, and all the sudden it's easy to see why your conclusion doesn't hold much water. This is completely different; apples and oranges.

Crown Equity Holdings, Inc., Announces DrStockPick.com Early Daily Stock Watch

(World Stock Wire Via Acquire Media NewsEdge) Las Vegas, NV - (WORLD STOCK WIRE) - February 6, 2009 -- DrStockPick.com, a division of Crown Equity Holdings Inc. (OTCBB: CRWE) tracks stocks daily and is pleased to offer its hot stock alerts. Investors can receive FREE Stock Alerts by visiting DrStockPick.com at the following link: http://www.drstockpick.com.

Workforce Management: At the Heart of the Contact Center Learn more, download free white paper.
The Modern Contact Center and Workforce Management�s Vital Role Learn more, download free white paper.
Realizing the Full Promise of Workforce Management Technology: Avoiding Mistakes That Short-Change Your Investment Learn more, download free white paper.
Convergence in Telecommunication Learn more, download free white paper.
Convergence in Telecommunication Learn more, download free white paper.
SIP Conferencing/Collaboration Learn more, download free white paper.


Today's early hot alerts include: Cavitation Technologies, Inc. (OTCBB: CVAT), Cord Blood America, Inc. (OTCBB: CBAI), Genta Incorporated (OTCBB: GNTA), MultiCell Technologies, Inc. (OTCBB: MCET), and SkyTerra Communications Inc. (OTCBB: SKYT).About Cavitation Technologies

Cavitation Technologies, Inc. is an engineering and manufacturing company focused on becoming the worldwide leader in the sales of nano technology-based cavitation systems. Although CTI is focused on applying its technology to modular, turn-key solutions to the biodiesel industry, the company recognizes potential commercial applications for nano-based cavitation technologies in markets such as water sanitation, alcoholic beverage instant aging, milk pasteurization and homogenization, chemical processing, water -- diesel emulsion, crude oil enhancement, and pharmaceuticals.


Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO West, October 27-29, 2009. Los Angeles, CA.
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO West, October 27-29, 2009. Los Angeles, CA.
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO West, October 27-29, 2009. Los Angeles, CA.
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO West, October 27-29, 2009. Los Angeles, CA.
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO West, October 27-29, 2009. Los Angeles, CA.
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO West, October 27-29, 2009. Los Angeles, CA.

About Cord Blood America

Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States.

About MultiCell Technologies

MultiCell Technologies, Inc., is a leading provider of liver cell-based products for drug discovery and therapeutic applications. The Company specializes in innovative cell immortalization technologies for reproducible creation of highly functional cell lines. MultiCell is now marketing liver cell lines via licensee, XenoTech, LLC and has additional pipeline products.

About SkyTerra Communications

SkyTerra Communications delivers mobile wireless voice and data services primarily for public safety, security, fleet management and asset tracking in the U.S. and Canada. The company's next-generation integrated satellite-terrestrial communications network is expected to provide seamless, transparent and ubiquitous wireless coverage of the United States and Canada to conventional handsets. When completed, the network will support communications in a variety of market segments, including public safety, homeland security, aviation, transportation and entertainment, by providing a platform for interoperable, user-friendly and feature-rich voice and high-speed data services.

ABOUT DRSTOCKPICK.COM

DrStockPick.com is a stock watch website that provides free daily alerts on stocks. DrStockPick.com's alerts are daily e-mail on stocks that are hot in the market. These include stocks with huge volume, penny stocks, stocks with technical indicators and much more.

DrStockPick.com also tracks small cap stocks that are on the brink of moving upwards. DrStockPick.com also features companies on its website with research report, analysis, and newsletters.

DrStockPick.com is an independent electronic publication that provides information on selected publicly traded companies. DrStockPick.com is not a registered investment advisor or broker-dealer. DrStockPick.com and Crown Equity Holdings, Inc., (CRWE) affiliates, officers, directors, contractors and employees, including may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.

We encourage investors to join to the FREE e-mail alerts by visiting: http://www.drstockpick.com

CONTACT: To feature a company on the web site please contacts us at: info@drstockpick.com.

ABOUT CROWN EQUITY HOLDINGS, INC.

Crown Equity Holdings, Inc. assists and consults with companies interested in becoming publicly traded in the United States. For further details, please visit the company's website at http://www.crownequityholding.com.

CONTACT: Crown Equity Holdings, Inc.: info@crownequityholdings.com

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not guarantees of future performance and involve significant risks and uncertainties. Actual results may vary materially from those in the forward-looking statements as a result of the effectiveness of management's strategies and decisions, general economic and business conditions, new or modified statutory or regulatory requirements and changing price and market conditions. No assurance can be given that these are all the factors that could cause actual results to vary materially from the forward-looking statements. The following report is neither an offer to buy or sell securities. Never invest in any stock featured on the DrStockPick Stock Watch website unless you can afford to lose your entire investment.

Kenneth Bosket, ken@crowntradingsystems.comCrown Equity Holdings, Inc.9663 Saint Claude AvenueLas Vegas, NV 89148USA

Phone: 702-448-543 Fax: 702-258-9007

Source: Crown Equity Holdings, Inc.Note: The following press release was submitted by: Crown Equity Holdings, Inc., and World Stock Wire, Inc. is not liable for the contents of this press release.

Copyright ? 2009 World Stock Wire, Inc. All rights reserved.

[ Back To TMCnet.com's Homepage ]

Haha, George got his postion...

...welcome to the party.

Here come the buyers!

Buh-Bye, Son. Time for class to start.

I'm through responding to...

...you. Grow up.

Further, I don't care if it does drop after the conference. I'm in this stock long, so today's, tomorrows, or next weeks price doesn't matter to me.

I'm in this stock because I've done my research and I believe in what they have going on.

The investors conference is just a place to give investors insight into what's going on with the company. I think they'll see the potential as well...but if not, I'm not concerned.

Genta has GREAT drugs in their pipeline and they will soon show that at this price, undervalued is an understatement.

I've been in this stock since it's lows...

...so I'm not some newbie, like yourself, trying to flip and make some small cash. I could've done that 100 times by now.

Genta will survive and flourish on its own merits, not some message board chatter. This company has a groundbreaking product on the market and two "ballgame changers" in their anticancer pipeline and is going to present to deep pocketed investors on Monday with a handful of clinical PROOF of efficacy and safety.

Don't act like I'm someone who just dropped by this stock lately, son. I've been here since before you knew what GNTA was.

Today is the day to get your ticket to the show. They'll be on sale starting at 9:30AM EST and will increase in price until 4:30PM EST. There will very likely be no news on FDA approval of ANY drugs, Genta or otherwise, at this meeting. So if that's what you're thinking, forget it. What you could very well expect is some big time financing and investment deals.

Monday Genta will broadcast to the world what they're doing as a groundbreaking drug company for hundreds BIG MONEY of investors.

Date:
9 Feb 2009 21:45 - 11 Feb 2009 21:45
Location:
United States

Now in its tenth year, the BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. Who Shouldn't Miss This Conference --Institutional Investors --Industry Analysts --Senior Biotechnology Executives Program Each year the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities.

Here is a "Daily Update" from the 2008 Conference that should give you a flavor of what to expect for 2009.

http://ceodailyupdate.wordpress.com/

Record number of institutional investors at CEO
Published February 15, 2008

"The final numbers are in and we have good reason to celebrate (perhaps we should get a three-day weekend?!) - there were a record number of institutional investors at the CEO & Investor Conference, 1,050 in total. Most of the more than 200 company presentations were full rooms, since in total we had more than 2000 participants. And obviously a lot of dealmaking and potential dealmaking was in the works with more than 1400 one-on-one meetings."

2008 BIO CEO & Investor Conference Slideshow

http://www.slide.com/r/0Ar2PwU12j-vX...94286778474910

Why Investors Attend:

* Hear from and meet one-on-one with management from the top biotechnology companies
* Evaluate fresh investment opportunities including compatible, complementary and competitive companies
* Attend candid panel discussions with leading clinical experts and company experts on the latest therapies and technologies in development
* Get a ‘big picture’ overview of the industry and the issues affecting investments now and in the future

Why Companies Attend:

* Present company story to an audience of target investors
* Meet one-on-one with new and current investors, analysts, investment bankers and other potential corporate partners
* Hear candid panel discussions and keynotes by veteran investment and company executives
* Network with peers, investors and potential partners attending the conference
* Get the pulse on the current and proposed investment trends in biotechnology

Genta Incorporated to Present at the 11th Annual BIO CEO & Investor Conference 02/02 08:05 AM

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)-- Genta Incorporated (GNTA:$0.0134,$-0.0011,-7.59%) announced today that the Company's Chairman and Chief Executive Officer, Dr. Raymond P. Warrell, Jr. , will provide a company overview and update of corporate activities at the 11th annual BIO CEO & Investor Conference. The presentation is scheduled for Monday, February 9th at 10:00 am ET at the Waldorf-Astoria Hotel, New York, NY. In addition, Dr. Warrell will be a panelist in the BIO CEO therapeutic workshop, "Oncology: The Forecast for the Melanoma Market - Partly Sunny or Mostly Cloudy", at 12:30 pm (ET) on Tuesday, February 10th. Expert panelists include Dr. Gary Schwartz, Chief, Melanoma/Sarcoma Service, Memorial Sloan Kettering Cancer Center, and Dr. Anna Pavlick, Assistant Professor of Medicine and Dermatology, and Director of the NYU Cancer Institute Melanoma Research Program, NYU Medical Center, who is an investigator on the Company's Phase 3 AGENDA trial of Genasense® in patients with advanced melanoma.

The presentation will be webcast and accessible at the Investor Relations section of the Company’s website at:

http://www.corporate-ir.net/ireye/co...tem_id=2079510

The presentation will be archived for 30 days. The panel will not be webcast.

This is going to be...

...an exciting day.

It will be very interesting to see how this plays today. We may not see that big dip a few minutes after the open. People are going to want to solidify their position prior to Monday morning. I think most of the profit takers probably got out yesterday.

GNTA hasn't had 2 consecutive "sell" volume days since January 12th and has only had 2 pullback days out of the last 10.

If you've got some cash laying around, you may want to consider getting a seat some time early; that dip may not happen because the dynamics are a bit different today as opposed to the prior few, so you run the risk waiting.

Not gonna work, George...

...too much on the line here for investors. Next week could bring some really good news to GNTA holders.

Perhaps you'd feel more comfortable with discussion over on the Circuit City board LOL

Genta first up!

I don't know if the time slot matters or not. One thing is certain, the hype will be at an all time high for investors and presenters alike and everyone will be wide awake.

In a class I took recently for my company, the instructor said that people only really remember 3 key points to any presentation, so no more than 3 key points should ever be used to sell an idea/business plan to someone else.

That being said, Genta presenting as one of the 1st slots is a really good place to be. Investors will be more prone to remember key points from the first few presentations and less from say the 47th.

Personally, I think it's a great time slot; Especially if the CEO of Genta brings the house down with compelling trial results.

2008 BIO CEO Slideshow

http://www.slide.com/r/0Ar2PwU12j-vXLFBnF-RGoD9fKm7yDqK?previous_view=TICKER&previous_action=TICKER_ITEM_CLICK&ciid=1369094286778474910

What will go down on Monday?

Why Investors Attend:

* Hear from and meet one-on-one with management from the top biotechnology companies
* Evaluate fresh investment opportunities including compatible, complementary and competitive companies
* Attend candid panel discussions with leading clinical experts and company experts on the latest therapies and technologies in development
* Get a ‘big picture’ overview of the industry and the issues affecting investments now and in the future

Why Companies Attend:

* Present company story to an audience of target investors
* Meet one-on-one with new and current investors, analysts, investment bankers and other potential corporate partners
* Hear candid panel discussions and keynotes by veteran investment and company executives
* Network with peers, investors and potential partners attending the conference
* Get the pulse on the current and proposed investment trends in biotechnology
Holding is online now Report Post Edit/Delete Message

Here is a "Daily Update" from the 2008 Conference that should give you a flavor of what to expect for 2009.

http://ceodailyupdate.wordpress.com/


Record number of institutional investors at CEO
Published February 15, 2008

"The final numbers are in and we have good reason to celebrate (perhaps we should get a three-day weekend?!) - there were a record number of institutional investors at the CEO & Investor Conference, 1,050 in total. Most of the more than 200 company presentations were full rooms, since in total we had more than 2000 participants. And obviously a lot of dealmaking and potential dealmaking was in the works with more than 1400 one-on-one meetings."

BIO CEO & Investor Conference Overview:


Date:
9 Feb 2009 21:45 - 11 Feb 2009 21:45
Location:
United States

Now in its tenth year, the BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. Who Shouldn't Miss This Conference --Institutional Investors --Industry Analysts --Senior Biotechnology Executives Program Each year the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities.